Diagnostic Challenges in Hereditary Angioedema with Normal C1-Inhibitor Levels: A Clinical Case Report

Juvenis scientia, 2025

Full text Open access: Gold Metadata (CSL-JSON)
DOI 10.32415/jscientia_2025_11_5_27-34
Data confidence 85 high
How this score is calculated

It is built from checkable properties of the record itself: whether the article has a DOI, how many independent sources confirmed its data, whether the required fields are filled in, and how recent the latest confirmation is. Disagreement between sources and a missing identifier lower it. A value of 80 or above means the record was published without further checking; 60 to 79 means it is published at reduced confidence, with a manual check advisable. A record verified by an editor by hand is never pushed below 90 by a recalculation. This scores our data about the article, not the article itself.

Abstract

Hereditary angioedema with normal C1‑inhibitor (HAE-nC1INH) remains a diagnostic challenge due to normal complement parameters and clinical similarity to histamine-­mediated angioedema, frequently leading to misdiagnosis and delayed initiation of appropriate therapy. The aim of this report was to demonstrate diagnostic reasoning in a clinically suspected case of HAE-nC1INH. We present a clinical case of a 25‑year-old woman with recurrent, non-urticarial edema involving the face and extremities, resistant to antihistamines and systemic corticosteroids. Clinical presentation, family history, and laboratory findings were analyzed, including complement C4 level, C1‑inhibitor activity, thyroid hormone levels, and serum 25‑hydroxyvitamin D. The patient exhibited normal C4 levels and borderline C1‑inhibitor activity in combination with a typical clinical phenotype and positive family history, supporting a probable diagnosis of HAE-nC1INH. A pronounced vitamin D deficiency was also identified. An allergic mechanism of angioedema was considered unlikely. This case underscores the importance of heightened clinical awareness in patients with recurrent angioedema of unclear origin. Early recognition of HAE-nC1INH facilitates timely initiation of targeted therapy and prevents prolonged ineffective treatment.